Format

Send to

Choose Destination
J Clin Pharmacol. 2008 Jul;48(7):837-48. doi: 10.1177/0091270008318218. Epub 2008 May 19.

Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease.

Author information

1
Metrum Research Group LLC, Tariffville, CT 06081, USA. billk@metrumrg.com

Abstract

This analysis quantifies the population pharmacokinetics of subcutaneous and intravenous epoetin delta, an epoetin produced in a human cell line, in pediatric patients with chronic kidney disease and estimates the effects of covariate factors on epoetin delta and epoetin alfa pharmacokinetic parameters. Erythropoietin serum concentration data, taken from a phase III study conducted in 60 patients aged 1 to 17 years, were best described by a 1-compartment model with first-order absorption and elimination. The typical point estimates were clearance (0.268 L/h), central volume of distribution (1.03 L), absorption rate constant (0.0554 h(-1)), and bioavailability (0.708) for a 35-kg male < or = 10 years who was predialysis and on subcutaneous epoetin delta treatment. Erythropoietin pharmacokinetic parameters were similar in pediatric patients as compared with adults when scaled by weight. The subcutaneous administration of epoetin alfa exhibited lower systemic bioavailability than subcutaneous administration of epoetin delta.

PMID:
18490498
DOI:
10.1177/0091270008318218
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center